$CSCIF News

Cosciens Biopharma Q1 EPS $2.90 Up From $(1.16) YoY, Sales $1.888M Up From $1.387M YoY

Cosciens Biopharma Q4 EPS $(0.69) Up From $(2.15) YoY, Sales $1.766M Down From $3.300M YoY

COSCIENS Biopharma to Stop Funding Aeterna Zentaris GmbH and Zentaris IVF GmbH

COSCIENS Provides Strategic Update

COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

COSCIENS Biopharma Signs 10-Year Exclusive Distribution Deal With Wuzhou For Macrilen In Hong Kong, Macao, Singapore, Guangdong, And Hainan, Including Minimum Initial Order Of €800,000

COSCIENS Biopharma Inc. Announces Leadership Change

COSCIENS Biopharma: Q3 Earnings Snapshot

COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders

COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders

Cosciens Biopharma announces receipt of Goodwood intended director nominations

COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders

Goodwood to Nominate New Directors for COSCIENS Biopharma Inc.

COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer

COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$13.64 loss in FY 2023)

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents